‘Enerzair Breezhaler,’ a three-in-one triple combination therapy for asthma, can now be prescribed at general hospitals in Korea.

According to industry sources, Novartis Korea’s triple combination drug ‘Enerzair Breezhaler (mometasone·indacaterol·glycopyrronium)’ that contains ICS (inhaled corticosteroids) · LABA (beta2-agonist) · LAMA (long-acting muscarinic antagonist) has passed the review of drug committees (DC) of ‘Big-5’ general hospitals including Samsung Medical Center (SMC), Seoul National University Hospital (SNUH), Seoul Asan Medical Center, and Severance Hospital.

The company had sought rapid entry into the market after it was approved for insurance benefit in Sep